About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

From Known to New Genes in Dyslipidemia

Clinicaltrials.gov identifier NCT03939039

Recruitment Status Recruiting

First Posted May 6, 2019

Last update posted May 6, 2019

Study Description

Brief summary:

The mechanism of the majority of the dyslipidemia is multifactorial at the molecular level and remains elusive in more than 50% of the patients in many clinical conditions. Next generation sequencing, a booming strategy, improves the molecular diagnosis efficiency in both monogenic and polygenic dyslipidemia. In order to decipher the mechanisms involved in the occurrence of dyslipidemia, in addition to the exploration of known candidate genes and Single Nucleotide Polymorphisms (SNP) involved in polygenic modulation, new genes involved in the regulation of lipoprotein metabolism or associated with lipids concentrations need to be sequenced in large groups of dyslipidemic patients. The goal of this project is to gain new insight into genotype/phenotype correlation.

  • Condition or Disease:Dyslipidemias
  • Intervention/Treatment:
  • Phase: N/A
Detailed Description


Study Design
  • Study Type: Observational
  • Estimated Enrollment: 5000 participants
  • Observational Model: Cohort
  • Time Perspective: Prospective
  • Official Title: Genetical Characterization of Patients Presenting With Dyslipidemia
  • Actual Study Start Date: January 2000
  • Estimated Primary Completion Date: December 2024
  • Estimated Study Completion Date: January 2025
Outcome Measures
  • Primary Outcome Measures: 1. Genetical exploration in dyslipidemic patients [ Time Frame: 25 years ]
    Deoxyribonucleic Acid (DNA) sequencing will allow the study of rare gene variants and their frequency in known and new genes in patients with dyslipidemia.
  • Biospecimen Retention: Samples With DNA

    Deoxyribonucleic Acid (DNA) of patients will sequenced using Sanger and Illumina Next-Generation Sequencing (NGS) methodology combined with PapilLyon, the pipeline developed by the Hospices Civils de Lyon (HCL) bioinformatics team, which allows more than 350 genes potentially involved in plasma lipoprotein metabolism to be explored.

Eligibility Criteria
  • Ages Eligible for Study: (Child, Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
  • Sampling Method: Non-Probability Sample
  • Study Population: Male or female patients with dyslipidemia

Inclusion Criteria:

- patients with a family documented history of primary hypercholesterolemia,
hypertriglyceridemia, hypobetalipoproteinemia, combined hypolipidemia and combined
hyperlipidemia according to the European Atherosclerosis Society and/or published

- patients with major secondary dyslipidemia.

Exclusion Criteria:

- inability to provide written informed consent

- lack of legal representative

Contacts and Locations

Contact: Mathilde Di Filippo 4 72 11 89 94 ext 33 mathilde.di-filippo@chu-lyon.fr

Contact: Oriane Marmontel 4 72 12 97 08 ext 33 oriane.marmontel@chu-lyon.fr


Laboratoire de Biologie Médicale Multi Sites, Centre de Biologie et de Pathologie Est, Département de biochimie et biologie moléculaire Grand Est

Sponsors and Collaborators

Hospices Civils de Lyon


Principal Investigator: Philippe Moulin, PhD Hospices Civils de Lyon

More Information
  • Responsible Party: Hospices Civils de Lyon
  • ClinicalTrials.gov Identifier: NCT03939039 History of Changes
  • Other Study ID Numbers: GENELIP
  • First Posted: May 6, 2019 Key Record Dates
  • Last Update Posted: May 6, 2019
  • Last Verified: May 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Dyslipidemias